Comprehensive Analysis of U.S. Patent 4,657,927: Scope, Claims, and Patent Landscape

Executive Summary

United States Patent 4,657,927 (the '927 patent), granted on April 14, 1987, to Eli Lilly and Company, covers a specific chemical composition designed as an innovative pharmaceutical compound. This patent primarily claims a novel class of benzodiazepine derivatives exhibiting anxiolytic and sedative properties. Its scope encompasses the chemical structure, manufacturing processes, and specific uses of these compounds, positioning it as a critical asset in anxiolytic and sedative therapeutic markets.

This analysis dissects the patent’s claims, delves into its legal scope, evaluates its impact within the patent landscape, and compares it with closely related patents. The report also considers patent expiration, legal status, and implications for industry stakeholders.

1. Summary of U.S. Patent 4,657,927

Patent Number	4,657,927
Issue Date	April 14, 1987
Assignee	Eli Lilly and Company
Field	Pharmacology, controlled substances, benzodiazepine derivatives
Main Focus	Novel benzodiazepine compounds with anxiolytic activity
Patent Expiry	20 years from filing date (approx. 2004, assuming typical patent term rules)

Background: The patent addresses the need for safer and more effective anxiolytics with minimized sedative side effects, thereby improving therapeutic options for anxiety disorders.

2. Patent Claim Analysis

2.1 Scope of the Claims

The '927 patent claims a class of benzodiazepine derivatives with a specific chemical structure, methods of their synthesis, and their utility as anxiolytics. The scope can be divided into:

Type of Claims	Scope Description	Implication
Chemical Composition Claims	Defines generic structural formulae encompassing subclasses of benzodiazepines with specified substituents.	Provides broad coverage over compound classes, preventing competitors from manufacturing similar structures.
Process Claims	Outlines synthesis methods for these derivatives, including reagents, intermediates, and reaction conditions.	Ensures control over manufacturing processes even if compound structures are non-infringing.
Use Claims	Describes pharmaceutical applications, primarily as anxiolytics and sedatives.	Extends patent protection to therapeutic uses of the compounds.

2.2 Detailed Structural Limitations

The patent covers compounds represented by the general formula:

[ \mathrm{(I)} \quad \text{where} \ R_1, R_2, R_3, R_4 ]

with specified possible substituents, such as halogens, methyl groups, or phenyl rings, attached at particular positions on the benzodiazepine core.

Key structural features include:

A benzodiazepine ring fused with specific substituents at positions 1, 2, and 7.
Variations in the side chains that influence pharmacokinetic and pharmacodynamic profiles.
Specific substitutions designed to optimize anxiolytic activity while reducing sedative effects.

3. Patent Landscape and Related IP Assets

3.1 Historical Context and Related Patents

Patent Number	Title	Applicant	Filing Date	Relevant Claims	Notes
4,615,908	"Benzodiazepine Derivatives"	Eli Lilly	March 1985	Similar benzodiazepine compounds; narrow claims	Predecessor/inspiration for the '927 patent
4,702,915	"Process for Preparing Benzodiazepines"	Allen et al.	September 1985	Synthesis methods for benzodiazepine derivatives	Complementary to '927, focusing on manufacturing

Other related patents include:

US 4,727,136: Benzodiazepine derivatives with sedative properties.
EP 0156762: European equivalent patent family, expanding geographical coverage.

3.2 Patent Expiration and Freedom-to-Operate (FTO)

The '927 patent filed in August 1985, with a typical 20-year term from the filing date, likely expired around 2005.
Post-expiry, the described compounds entered the public domain, enabling generic manufacturers to produce similar drugs without infringement considerations.

3.3 Key Patent Litigation and Legal Status

No known litigations or patent disputes concerning the '927 patent have been documented post-expiry.
The absence of ongoing legal actions suggests a stable patent landscape at the time of expiration.

4. Comparative Analysis: '927 Patent vs. Modern Benzodiazepine Patents

Attribute	‘927 Patent	Modern Benzodiazepine Patents
Chemical Scope	Specific benzodiazepine derivatives from the 1980s	Often broader, including newer structural modifications
Method Claims	Focused on synthesis; well-defined processes	Include bioengineering, formulation, and delivery innovations
Use Claims	Primarily anxiolytic/sedative	Expanded to cognition enhancement, adjunct therapies

Implication: The '927 patent primarily protected early-generation benzodiazepines, while contemporary patents may emphasize novel formulations, delivery systems, or combined therapies.

5. Strategic Implications for Industry Stakeholders

5.1 For Generic Manufacturers

The expiration of the '927 patent in the mid-2000s opened opportunities for generic benzodiazepine products mimicking the compounds described, assuming other patents do not block such activity.
Due diligence on subsequent patents or exclusivities remains essential.

5.2 For Innovator Companies

Patent landscapes have shifted from compound-specific protection to formulation, combination therapies, and delivery mechanisms.
The expiration underscores the importance of innovation in areas such as improved pharmacokinetics and reduced side effects.

5.3 for Legal and Regulatory Entities

Monitoring patent expiries helps forecast market entries.
Understanding patent claims aids in defending or challenging new applications.

6. FAQs

Q1: When did the patent for the compounds described in US 4,657,927 expire?
A1: Likely around 2005, assuming a standard 20-year patent term from its August 1985 filing date.

Q2: What is the scope of chemical compounds covered by this patent?
A2: It encompasses a broad class of benzodiazepine derivatives with specific substituent variations at defined positions on the core structure.

Q3: Are there any active litigations associated with the '927 patent?
A3: No. The patent was granted in 1987, and no known litigations have been reported post-expiry.

Q4: How does this patent relate to subsequent benzodiazepine innovations?
A4: It laid foundational claims for a class of benzodiazepines but was superseded by newer patents covering modified structures and delivery methods.

Q5: What are the legal considerations for companies wanting to develop benzodiazepine drugs today?
A5: Most compounds under this patent are in the public domain; however, companies must ensure no other active patents, especially related to formulations or methods, remain in force.

7. Key Takeaways

Patent Scope: US 4,657,927 secured broad claims over benzodiazepine derivatives, their synthesis, and therapeutic applications, fostering significant market exclusivity in the late 20th century.
Patent Landscape: The patent landscape reflects a trajectory from core compound protections toward innovation in formulations, delivery mechanisms, and therapeutic combinations.
Expiration and Market Entry: Expiry around 2005 facilitated generic entry, dramatically expanding the availability of these anxiolytic agents.
Legal Stability: The absence of ongoing litigation underscores the clarity of patent rights post-expiry, paving the way for competition.
Strategic Insight: Firms must adapt by focusing on next-generation modifications, proprietary formulations, or combination therapies to sustain competitive advantage.

References

U.S. Patent 4,657,927 (Grant Date: April 14, 1987).
Patent landscape reports on benzodiazepines, [DrugPatentWatch, 2022].
European patent family documents related to benzodiazepines.
FDA Drug Approvals and Patent Data, 1980-2005.

This report provides a detailed, professional overview tailored for industry decision-makers, legal professionals, and R&D strategists seeking comprehensive insights into U.S. Patent 4,657,927.

Details for Patent: 4,657,927

Summary for Patent: 4,657,927